Generic Name and Formulations:
Velaglucerase alfa 400 Units/vial; lyophilized pwd for IV infusion after reconstitution; preservative-free.
Shire US, Inc.
Indications for VPRIV:
Long-term enzyme replacement therapy (ERT) in patients with Type 1 Gaucher disease.
Adults and Children:
<4yrs: not established. Give by IV infusion over 60 minutes. Individualize. ≥4yrs: 60 Units/kg every other week; adjust dose based on therapeutic goals. Begin treatment with Vpriv at the same dose when switching from imiglucerase.
Monitor for hypersensitivity reactions; immediately discontinue and treat appropriately if occur. Temporarily discontinue and resume with increased infusion time, slowing infusion rate, or administer antihistamines, antipyretics, and/or corticosteroids if infusion-related reactions occur. Elderly. Pregnancy (Cat.B). Nursing mothers.
Lysosomal glucocerebroside-specific enzyme.
Infusion-related reactions, headache, dizziness, abdominal pain, nausea, back pain, joint pain, upper respiratory tract infection, activated PTT prolonged, fatigue/asthenia, pyrexia.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Nomophobia: The Modern-Day Pathology
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Emerging Theories in the Pathophysiology of MDD: Could the Opioid System Be Involved?
- Ketamine Infusions Reduce Suicidal Ideation in Depression: Characterizing Different Responses
- Cognitive Behavioral Therapy May Alter Suicidal Ideation in Anxiety Disorders
- Text Message Reminders Improve Medication Adherence in Bipolar I Disorder
- Improving Medication Adherence in ADHD Lowers Risk for Oppositional Defiant Disorder, Conduct Disorder in Adulthood
- High Suicidality Among Children With ADHD Mediated by Family Functioning, Psychiatry Comorbidities
- Pilot Study Investigates Lithium vs Quetiapine for Bipolar Spectrum Disorder
- How Personalized Hospital Ratings May Drive Patient-Specific Care in the Digital Age